Persistence of glutamic acid decarboxylase antibody (GADA) is associated with clinical characteristics of latent autoimmune diabetes in adults: a prospective study with 3‐year follow‐up

Authors:

Abstract
Background Latent autoimmune diabetes in adults (LADA) is a form of autoimmune diabetes with heterogeneous features. This study aimed to investigate the persistent status of glutamic acid decarboxylase antibody (GADA) in patients with LADA and its association with clinical characteristics. Methods This 3-year follow-up study enrolled 107 LADA and 40 type 2 diabetes mellitus (T2DM) patients from Oct 2005 to Dec 2013. GADA titer, epitopes, and clinical characteristics (including fasting C-peptide and HbA1c) in LADA patients were assayed annually. HLA-DQ genotypes were also analyzed. The relationship between the persistence of GADA and clinical characteristics were investigated in LADA patients. Results After 3-year follow-up, 36.5% (39/107) LADA patients remained GADA-positive (persistently positive group); 19.6% (21/107) patients fluctuated positively and negatively (fluctuating group); while 43.9% (47/107) patients became GADA-negative, among which 61.7% (29/47) seroconversions occurred within 6 months follow-up (transiently positive group). The GADA persistently positive group possessed higher titer of GADA than transiently positive group and fluctuant group (all P =0.000),higher reactivities to middle and C-terminal regions of GAD65 than those in transiently positive group (P = 0.001 and P = 0.000, respectively), and lower baseline fasting C-peptide level than T2DM patients and transiently positive group [415(31-1862) vs. 620(220-1658) pmol/L, P = 0.014; 415(31 ~ 1862) vs. 705(64 ~ 1541) pmol/L, P = 0.017, respectively]. The GADA transiently positive group retained a higher HbA1C level when compared to T2DM patients (P = 0.023). In addition, the three LADA groups shared similar frequencies of HLA-DQ susceptible haplotypes that were higher as compared with T2DM. The GADA persistently positive group had a higher annual declining rate in fasting C-peptide than T2DM patients [-14%(-174% ~ 33%) vs. -1%(-27% ~ 28%), P = 0.007]. Conclusion LADA patients with GADA transient positivity account for a large proportion, whose clinical characteristics and HLA-DQ haplotypes are different from that of T2DM. The patients with high titer GADA and reactivities to GADA65 middle and C-terminal regions showed a persistent GADA positivity, in which a worse baseline and accelerated decline of beta cell function need early intervention in the practice.
Funding Information
  • National Key Technology R&D Programme (2012BAI02B04)
  • National Clinical Research Centre for Metabolic Disease (2013BAI09B12)

This publication has 22 references indexed in Scilit: